Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ADOC - FR0011184241 - Common Stock

7.11 EUR
-0.43 (-5.7%)
Last: 12/8/2025, 5:15:15 PM
Fundamental Rating

2

ADOC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. Both the profitability and financial health of ADOC have multiple concerns. While showing a medium growth rate, ADOC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADOC has reported negative net income.
In the past year ADOC has reported a negative cash flow from operations.
In the past 5 years ADOC always reported negative net income.
In the past 5 years ADOC always reported negative operating cash flow.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

The Return On Assets of ADOC (-35.65%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -35.65%
ROE N/A
ROIC N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

ADOC's Gross Margin of 79.22% is fine compared to the rest of the industry. ADOC outperforms 67.47% of its industry peers.
The Profit Margin and Operating Margin are not available for ADOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADOC has more shares outstanding
ADOC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADOC has been reduced compared to a year ago.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ADOC has an Altman-Z score of 0.30. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.30, ADOC perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.3
ROIC/WACCN/A
WACC7.72%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ADOC has a Current Ratio of 1.14. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC's Current ratio of 1.14 is on the low side compared to the rest of the industry. ADOC is outperformed by 71.08% of its industry peers.
ADOC has a Quick Ratio of 1.12. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC has a Quick ratio of 1.12. This is in the lower half of the industry: ADOC underperforms 66.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.12
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.21%, which is quite impressive.
The Revenue has grown by 1879.16% in the past year. This is a very strong growth!
ADOC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.18% yearly.
EPS 1Y (TTM)63.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.8%
Revenue 1Y (TTM)1879.16%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -36.12% on average over the next years. This is quite bad
ADOC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.00% yearly.
EPS Next Y-90.2%
EPS Next 2Y-42.41%
EPS Next 3Y-28.13%
EPS Next 5Y-36.12%
Revenue Next Year-51.75%
Revenue Next 2Y-37.38%
Revenue Next 3Y-50%
Revenue Next 5Y-18%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADOC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A cheap valuation may be justified as ADOC's earnings are expected to decrease with -28.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.41%
EPS Next 3Y-28.13%

More info and screens

0

5. Dividend

5.1 Amount

ADOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (12/8/2025, 5:15:15 PM)

7.11

-0.43 (-5.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-15 2025-10-15
Earnings (Next)04-15 2026-04-15/amc
Inst Owners7.95%
Inst Owner ChangeN/A
Ins Owners3.79%
Ins Owner ChangeN/A
Market Cap130.18M
Revenue(TTM)10.35M
Net Income(TTM)-9.71M
Analysts84.44
Price Target15.5 (118%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.51%
PT rev (3m)8.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)14.47%
EPS NY rev (3m)-67.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.57
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.22%
FCFM N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.62%
Cap/Sales 2.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.12
Altman-Z 0.3
F-Score4
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)32.19%
Cap/Depr(5y)28.97%
Cap/Sales(3y)3.68%
Cap/Sales(5y)12.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.8%
EPS Next Y-90.2%
EPS Next 2Y-42.41%
EPS Next 3Y-28.13%
EPS Next 5Y-36.12%
Revenue 1Y (TTM)1879.16%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%N/A
Revenue Next Year-51.75%
Revenue Next 2Y-37.38%
Revenue Next 3Y-50%
Revenue Next 5Y-18%
EBIT growth 1Y47.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-75.21%
EBIT Next 3Y-29.09%
EBIT Next 5YN/A
FCF growth 1Y-28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.12%
OCF growth 3YN/A
OCF growth 5YN/A

ADOCIA SAS / ADOC.PA FAQ

What is the fundamental rating for ADOC stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA.


Can you provide the valuation status for ADOCIA SAS?

ChartMill assigns a valuation rating of 0 / 10 to ADOCIA SAS (ADOC.PA). This can be considered as Overvalued.


Can you provide the profitability details for ADOCIA SAS?

ADOCIA SAS (ADOC.PA) has a profitability rating of 1 / 10.


How financially healthy is ADOCIA SAS?

The financial health rating of ADOCIA SAS (ADOC.PA) is 2 / 10.